Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opus Genetics Inc (IRD)

Opus Genetics Inc (IRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 333,786
  • Shares Outstanding, K 68,964
  • Annual Sales, $ 10,990 K
  • Annual Income, $ -57,530 K
  • EBIT $ -65 M
  • EBITDA $ -65 M
  • 60-Month Beta 0.45
  • Price/Sales 24.34
  • Price/Cash Flow N/A
  • Price/Book 50.30

Options Overview Details

View History
  • Implied Volatility 190.22% (-503.41%)
  • Historical Volatility 94.49%
  • IV Percentile 25%
  • IV Rank 11.53%
  • IV High 1,405.35% on 03/11/26
  • IV Low 31.89% on 09/16/25
  • Expected Move (DTE 7) 0.78 (15.58%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 58
  • Volume Avg (30-Day) 566
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 8,917
  • Open Int (30-Day) 9,497
  • Expected Range 4.24 to 5.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate -0.14
  • Low Estimate -0.19
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.29 +52.89%
on 02/23/26
5.30 -5.09%
on 03/10/26
+1.39 (+38.19%)
since 02/13/26
3-Month
1.88 +167.55%
on 01/12/26
5.30 -5.09%
on 03/10/26
+2.67 (+113.14%)
since 12/12/25
52-Week
0.65 +673.85%
on 04/10/25
5.30 -5.09%
on 03/10/26
+4.10 (+440.86%)
since 03/13/25

Most Recent Stories

More News
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of...

IRD : 5.06 (+4.55%)
Opus Genetics to Present at Upcoming Investor Conferences in March 2026

RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing...

IRD : 5.06 (+4.55%)
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months  Early signals of functional and...

IRD : 5.06 (+4.55%)
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics , Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 5.06 (+4.55%)
Opus Genetics Announces $25 Million Private Placement

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 5.06 (+4.55%)
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 5.06 (+4.55%)
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund Clinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026 MERTK-related retinitis pigmentosa...

IRD : 5.06 (+4.55%)
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

- Multi-asset pipeline with significant targeted data readouts and milestones - - Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 - - Supplemental New Drug...

IRD : 5.06 (+4.55%)
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside

These biotech bets are only for investors who can stomach volatility.

EYPT : 13.18 (-6.06%)
IRD : 5.06 (+4.55%)
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

IRD : 5.06 (+4.55%)

Business Summary

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills,...

See More

Key Turning Points

3rd Resistance Point 5.48
2nd Resistance Point 5.32
1st Resistance Point 5.08
Last Price 5.06
1st Support Level 4.69
2nd Support Level 4.53
3rd Support Level 4.29

See More

52-Week High 5.30
Last Price 5.06
Fibonacci 61.8% 3.52
Fibonacci 50% 2.98
Fibonacci 38.2% 2.43
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar